Matching articles for "glycopyrrolate"
Issue 1758 · July 6, 2026
Breztri Aerosphere for Asthma

Breztri Aerosphere (AstraZeneca), a three-drug inhaler containing the inhaled corticosteroid (ICS) budesonide, the long-acting antimuscarinic agent (LAMA) glycopyrrolate, and the long-acting beta 2 -agonist…

Med Lett Drugs Ther. 2026 Jul 6; 68(1758):108-9 doi:10.58347/tml.2026.1758c
Breztri Aerosphere (AstraZeneca), a three-drug inhaler containing the inhaled corticosteroid (ICS) budesonide, the long-acting antimuscarinic agent (LAMA) glycopyrrolate, and the long-acting beta 2 -agonist (LABA) formoterol fumarate, has been approved by the FDA for maintenance treatment of asthma in patients ≥12 years old. It was approved in 2020 for treatment of chronic obstructive pulmonary disease (COPD). Breztri Aerosphere is the second ICS/LAMA/LABA combination to become available for treatment of asthma. Trelegy Ellipta , which contains the ICS fluticasone, the LAMA umeclidinium, and the LABA vilanterol, is FDA-approved for maintenance treatment of asthma in adults.
Issue 1710 · September 2, 2024
Drugs for COPD

The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD…

Med Lett Drugs Ther. 2024 Sep 2; 66(1710):137-44 doi:10.58347/tml.2024.1710a
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines for treatment of COPD were updated recently. Treatment of acute exacerbations is not discussed here. Drugs available for treatment of COPD are listed in Tables 1 and 3.
Issue 1710 · September 2, 2024
Comparison Table: Inhaled Drugs for Treatment of COPD (online only)

View the Comparison Table: Inhaled Drugs for Treatment of COPD

Med Lett Drugs Ther. 2024 Sep 2; 66(1710):e143-7 doi:10.58347/tml.2024.1710b
View the Comparison Table: Inhaled Drugs for Treatment of COPD
Issue 1709 · August 19, 2024
Sofpironium (Sofdra) for Primary Axillary Hyperhidrosis

The FDA has approved a 12.45% gel formulation of the anticholinergic drug sofpironium ( Sofdra – Botanix) for treatment of primary axillary hyperhidrosis (excessive underarm sweating) in patients ≥9 years…

Med Lett Drugs Ther. 2024 Aug 19; 66(1709):133-4 doi:10.58347/tml.2024.1709c
The FDA has approved a 12.45% gel formulation of the anticholinergic drug sofpironium ( Sofdra – Botanix) for treatment of primary axillary hyperhidrosis (excessive underarm sweating) in patients ≥9 years old.
Issue 1707 · July 22, 2024
Brella Sweat Control Patch for Primary Axillary Hyperhidrosis (online only)

Brella Sweat Control Patch (Candesant Biomedical), a sodium-containing transdermal patch, has been cleared by the FDA for in-office treatment of primary axillary hyperhidrosis in adults. It is the first patch…

Med Lett Drugs Ther. 2024 Jul 22; 66(1707):e125-6 doi:10.58347/tml.2024.1707i
Brella Sweat Control Patch (Candesant Biomedical), a sodium-containing transdermal patch, has been cleared by the FDA for in-office treatment of primary axillary hyperhidrosis in adults. It is the first patch to be approved in the US for this indication.
Issue 1643 · February 7, 2022
Glycopyrrolate (Dartisla ODT) for Peptic Ulcer Symptoms

The FDA has approved adjunctive treatment with Dartisla ODT (Edenbridge), a new orally disintegrating tablet (ODT) formulation of the anticholinergic drug glycopyrrolate, to reduce symptoms of a peptic ulcer.…

Med Lett Drugs Ther. 2022 Feb 7; 64(1643):24
The FDA has approved adjunctive treatment with Dartisla ODT (Edenbridge), a new orally disintegrating tablet (ODT) formulation of the anticholinergic drug glycopyrrolate, to reduce symptoms of a peptic ulcer. Glycopyrrolate oral tablets ( Robinul, Robinul Forte, and generics) were approved for the same indication in 1961.
Issue 1606 · September 7, 2020
Drugs for COPD

The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several guidelines and…

Med Lett Drugs Ther. 2020 Sep 7; 62(1606):137-44
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several guidelines and review articles on COPD treatment have been published in recent years. Treatment of acute exacerbations is not discussed here.
Issue 1606 · September 7, 2020
Comparison Table: Inhaled Long-Acting Bronchodilators for Treatment of COPD (online only)

View the Comparison Table: Inhaled Long-Acting Bronchodilators for Treatment of COPD

Med Lett Drugs Ther. 2020 Sep 7; 62(1606):e146-7
View the Comparison Table: Inhaled Long-Acting Bronchodilators for Treatment of COPD
Issue 1606 · September 7, 2020
Comparison Table: Inhaled Corticosteroids for Treatment of COPD (online only)

View the Comparison Table: Inhaled Corticosteroids for Treatment of COPD

Med Lett Drugs Ther. 2020 Sep 7; 62(1606):e148-9
View the Comparison Table: Inhaled Corticosteroids for Treatment of COPD
Issue 1606 · September 7, 2020
Table: Correct Use of Inhalers for COPD (online only)

View the Table: Correct Use of Inhalers for COPD

Med Lett Drugs Ther. 2020 Sep 7; 62(1606):e150-4
View the Table: Correct Use of Inhalers for COPD
Issue 1581 · September 23, 2019
Duaklir Pressair: Another LAMA/LABA Inhaler for COPD

The FDA has approved Duaklir Pressair (Circassia), a fixed-dose combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide and the longacting beta 2 -adrenergic agonist (LABA) formoterol…

Med Lett Drugs Ther. 2019 Sep 23; 61(1581):149-51
The FDA has approved Duaklir Pressair (Circassia), a fixed-dose combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide and the longacting beta 2 -adrenergic agonist (LABA) formoterol fumarate, for maintenance treatment of chronic obstructive pulmonary disease (COPD). Aclidinium/formoterol is the fifth LAMA/LABA combination to be approved in the US for this indication.
Issue 1564 · January 28, 2019
Revefenacin (Yupelri) for COPD

The FDA has approved revefenacin ( Yupelri – Mylan/Theravance Biopharma), a long-acting antimuscarinic agent (LAMA) administered once daily by standard jet nebulizer, for maintenance treatment of chronic…

Med Lett Drugs Ther. 2019 Jan 28; 61(1564):14-5
The FDA has approved revefenacin ( Yupelri – Mylan/Theravance Biopharma), a long-acting antimuscarinic agent (LAMA) administered once daily by standard jet nebulizer, for maintenance treatment of chronic obstructive pulmonary disease (COPD). Revefenacin is the second nebulized LAMA to be approved for this indication; glycopyrrolate (Lonhala Magnair) , which is administered twice daily with a portable handheld nebulizer, was the first.
Issue 1564 · January 28, 2019
Qbrexza - A Glycopyrronium Cloth for Axillary Hyperhidrosis

Qbrexza (Dermira), a premoistened cloth containing the long-acting anticholinergic drug glycopyrronium, has been approved by the FDA for once-daily topical treatment of excessive underarm sweating (primary…

Med Lett Drugs Ther. 2019 Jan 28; 61(1564):10-1
Qbrexza (Dermira), a premoistened cloth containing the long-acting anticholinergic drug glycopyrronium, has been approved by the FDA for once-daily topical treatment of excessive underarm sweating (primary axillary hyperhidrosis) in patients ≥9 years old. Glycopyrronium bromide (glycopyrrolate) has been available for years in parenteral, inhalation, and oral formulations for treatment of multiple conditions.
Issue 1547 · May 21, 2018
Trelegy Ellipta - A Three-Drug Inhaler for COPD

The FDA has approved Trelegy Ellipta (GSK), a fixed-dose combination of the inhaled corticosteroid (ICS) fluticasone furoate, the long-acting antimuscarinic agent (LAMA) umeclidinium, and the long-acting beta…

Med Lett Drugs Ther. 2018 May 21; 60(1547):86-8
The FDA has approved Trelegy Ellipta (GSK), a fixed-dose combination of the inhaled corticosteroid (ICS) fluticasone furoate, the long-acting antimuscarinic agent (LAMA) umeclidinium, and the long-acting beta 2 -agonist (LABA) vilanterol. It is available as a dry powder inhaler for once-daily maintenance treatment of COPD and to reduce COPD exacerbations in patients with a history of exacerbations. Trelegy Ellipta is the first three-drug inhaler for treatment of COPD to become available in the US.
Issue 1545 · April 23, 2018
Nebulized Glycopyrrolate (Lonhala Magnair) for COPD

The FDA has approved an inhalation solution formulation of the long-acting antimuscarinic agent (LAMA) glycopyrrolate ( Lonhala Magnair – Sunovion) for maintenance treatment of chronic obstructive pulmonary…

Med Lett Drugs Ther. 2018 Apr 23; 60(1545):72
The FDA has approved an inhalation solution formulation of the long-acting antimuscarinic agent (LAMA) glycopyrrolate ( Lonhala Magnair – Sunovion) for maintenance treatment of chronic obstructive pulmonary disease (COPD). The new formulation is delivered using a portable, handheld, electronic nebulizer. Glycopyrrolate is also available as a dry powder inhaler, both alone (Seebri Neohaler) and in combination with indacaterol (Utibron Neohaler) , and as a metered-dose inhaler in combination with formoterol (Bevespi Aerosphere) . Lonhala Magnair is the first nebulized LAMA to become available in the US.
Issue 1518 · April 10, 2017
Drugs for COPD

The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Updated guidelines for…

Med Lett Drugs Ther. 2017 Apr 10; 59(1518):57-62
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Updated guidelines for treatment of COPD have been published in recent years.
Issue 1518 · April 10, 2017
Comparison Table: Inhaled Long-Acting Bronchodilators for COPD (online only)

View the Comparison Table: Inhaled Long-Acting Bronchodilators for COPD

Med Lett Drugs Ther. 2017 Apr 10; 59(1518):e64-5
View the Comparison Table: Inhaled Long-Acting Bronchodilators for COPD
Issue 1518 · April 10, 2017
Table: Correct Use of Inhalers for COPD (online only)

View the Table: Correct Use of Inhalers for COPD

Med Lett Drugs Ther. 2017 Apr 10; 59(1518):e67-71
View the Table: Correct Use of Inhalers for COPD
Issue 1505 · October 10, 2016
Glycopyrrolate/Formoterol (Bevespi Aerosphere) for COPD

The FDA has approved a fixed-dose combination of the long-acting anticholinergic glycopyrrolate and the long-acting beta 2- adrenergic agonist (LABA) formoterol ( Bevespi Aerosphere – AstraZeneca) for…

Med Lett Drugs Ther. 2016 Oct 10; 58(1505):130-2
The FDA has approved a fixed-dose combination of the long-acting anticholinergic glycopyrrolate and the long-acting beta 2- adrenergic agonist (LABA) formoterol ( Bevespi Aerosphere – AstraZeneca) for long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Glycopyrrolate/formoterol is the fourth long-acting anticholinergic/LABA combination to be approved in the US, but the first to become available in a metered-dose inhaler. Glycopyrrolate/indacaterol (Utibron Neohaler) , umeclidinium/vilanterol (Anoro Ellipta) , and tiotropium/olodaterol (Stiolto Respimat) were approved earlier.
Issue 1491 · March 28, 2016
Seebri Neohaler and Utibron Neohaler for COPD

The FDA has approved two new inhalers for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). Seebri Neohaler (Novartis) contains the long-acting anticholinergic glycopyrrolate.…

Med Lett Drugs Ther. 2016 Mar 28; 58(1491):39-41
The FDA has approved two new inhalers for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). Seebri Neohaler (Novartis) contains the long-acting anticholinergic glycopyrrolate. Utibron Neohaler (Novartis) contains both glycopyrrolate and the long-acting beta 2 -adrenergic agonist (LABA) indacaterol. Glycopyrrolate/indacaterol is the third fixed-dose combination of a long-acting anticholinergic and a LABA to become available in the US; umeclidinium/vilanterol (Anoro Ellipta) and tiotropium/olodaterol (Stiolto Respimat) were approved earlier.
Issue 1482 · November 23, 2015
Tiotropium/Olodaterol (Stiolto Respimat) for COPD

The FDA has approved a fixed-dose, orally inhaled combination of the long-acting anticholinergic tiotropium and the long-acting beta 2 -adrenergic agonist olodaterol ( Stiolto Respimat — Boehringer…

Med Lett Drugs Ther. 2015 Nov 23; 57(1482):161-2
The FDA has approved a fixed-dose, orally inhaled combination of the long-acting anticholinergic tiotropium and the long-acting beta 2 -adrenergic agonist olodaterol ( Stiolto Respimat — Boehringer Ingelheim) for long-term, once-daily, maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD). It is not approved for treatment of acute exacerbations of COPD or for treatment of asthma. Tiotropium (Spiriva Handihaler , Spiriva Respimat) and olodaterol (Striverdi Respimat) are also available separately for once-daily treatment of COPD.
Issue 1355 · January 10, 2011 Free
In Brief: Glycopyrrolate Oral Solution for Sialorrhea

Glycopyrrolate ( Robinul , and others), a synthetic muscarinic receptor antagonist, has been used off-label for many years for treatment of excessive drooling in patients with Parkinson’s disease, in…

Med Lett Drugs Ther. 2011 Jan 10; 53(1355):4
Glycopyrrolate ( Robinul , and others), a synthetic muscarinic receptor antagonist, has been used off-label for many years for treatment of excessive drooling in patients with Parkinson’s disease, in patients taking clozapine for schizophrenia, and in developmentally disabled children. 1-3 It has now been approved by the FDA as Cuvposa (Shionogi) for use specifically in children 3-16 years old with severe chronic drooling due to a neurologic condition, such as cerebral palsy. It is being marketed as an oral solution, which will permit more precise weight-based dosing than was possible with the oral tablets used in the past. As with other anticholinergic drugs, dry mouth, constipation, flushing and nasal congestion can occur. Since glycopyrrolate decreases secretion not only of saliva, but also of sweat, overheating due to high ambient temperatures or excessive exercise could be dangerous for patients who take it. 1. ME Arbouw et al. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology 2010; 74:1203. 2. CS Liang et al. Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study. Schizophren Res 2010; 119:138. 3. RJ Mier et al. Treatment of sialorrhea with glycopyrrolate: a double-blind, dose-ranging study. Arch Pediatr Adolesc Med 2000; 154:1214. Download U.S. English